T2 Biosystems
T2 Biosystems Preliminary Q4 Product Revenues Jump 37 Percent
The Lexington, Massachusetts-based company also reported preliminary full-year product revenues rose 23 percent on sepsis test sales.
In Brief This Week: Natera, Enzo Biochem, Tempus, Vizgen, Complete Genomics, Parse Biosciences, More
News items for the week of Dec. 16, 2024.
T2 Biosystems Receives Delisting Notice From Nasdaq
The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.
T2 Biosystems to Outlicense Infectious Disease Testing Technology
The firm said its T2 Magnetic Resonance technology for testing whole-blood samples could be paired with fluorescence and other testing methods.
In Brief This Week: Oncocyte, Lucid Diagnostics, T2 Biosystems, All of Us, Myriad Genetics, More
News items for the week of Nov. 11, 2024
May 15, 2024
T2 Biosystems to Raise $8M in Private Placement
Nov 27, 2023